A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex
Maya Michon,Andreas Müller-Schiffmann,Anuradha F. Lingappa,Shao Feng Yu,Li Du,Fred Deiter,Sean Broce,Suguna Mallesh,Jackelyn Crabtree,Usha F. Lingappa,Amanda Macieik,Lisa Müller,Philipp Niklas Ostermann,Marcel Andrée,Ortwin Adams,Heiner Schaal,Robert J. Hogan,Ralph A. Tripp,Umesh Appaiah,Sanjeev K. Anand,Thomas W. Campi,Michael J. Ford,Jonathan C. Reed,Jim Lin,Olayemi Akintunde,Kiel Copeland,Christine Nichols,Emma Petrouski,Ana R. Moreira,I-ting Jiang,Nicholas DeYarman,Ian Brown,Sharon Lau,Ilana Segal,Danielle Goldsmith,Shi Hong,Vinod Asundi,Erica M. Briggs,Ngwe Sin Phyo,Markus Froehlich,Bruce Onisko,Kent Matlack,Debendranath Dey,Jaisri R. Lingappa,Dharma M. Prasad,Anatoliy Kitaygorodskyy,Dennis Solas,Homer Boushey,John Greenland,Satish Pillai,Michael K. Lo,Joel M. Montgomery,Christina F. Spiropoulou,Carsten Korth,Suganya Selvarajah,Kumar Paulvannan,Vishwanath R. Lingappa
DOI: https://doi.org/10.1098/rsob.230363
2024-06-20
Open Biology
Abstract:We present a novel small molecule antiviral chemotype that was identified by an unconventional cell-free protein synthesis and assembly-based phenotypic screen for modulation of viral capsid assembly. Activity of PAV-431, a representative compound from the series, has been validated against infectious viruses in multiple cell culture models for all six families of viruses causing most respiratory diseases in humans. In animals, this chemotype has been demonstrated efficacious for porcine epidemic diarrhoea virus (a coronavirus) and respiratory syncytial virus (a paramyxovirus). PAV-431 is shown to bind to the protein 14-3-3, a known allosteric modulator. However, it only appears to target the small subset of 14-3-3 which is present in a dynamic multi-protein complex whose components include proteins implicated in viral life cycles and in innate immunity. The composition of this target multi-protein complex appears to be modified upon viral infection and largely restored by PAV-431 treatment. An advanced analog, PAV-104, is shown to be selective for the virally modified target, thereby avoiding host toxicity. Our findings suggest a new paradigm for understanding, and drugging, the host–virus interface, which leads to a new clinical therapeutic strategy for treatment of respiratory viral disease.
biochemistry & molecular biology